Rating: HOLD
| Metric | Value |
|---|---|
| Current Price | $212 |
| Triangulated Fair Value | $159 |
| 12-mo Scenario PWEV | $204 |
| Implied Return | -25% |
| Forward P/E | 19.7x |
| Market Cap | $24B |
| 52-Week Range | $162 – $213 |
Methodology: Valuation triangulated across five independent anchors — Monte Carlo (Student-t + regime switching), an independent DCF, peer re-rating, a sum-of-parts, and a scenario-weighted PWEV. Figures reconciled to Alpha Vantage 2026-06-27. Each chart below sits with the part of the thesis it evidences.
Investment Thesis
The bull case — 'Bull — Re-Rate' (8% weight) — targets $361, +71% vs spot. It needs Gross Margin to surprise to the upside.
The dashboard below is the whole argument on one page: spot ($212) against each valuation anchor, the scenario tree, technicals and the options-implied move.
Anti-Thesis (The Real Bear Case)
The structural case — 'Structural — Reimbursement / In-House Testing' (20%) — targets $90, -58% vs spot. This sits below the 52-week low — a genuine structural impairment, not a mild pullback.
Key Debate
Gross Margin explains 57% of Monte Carlo outcome variance — the single variable that decides which side is right.
Earnings-Call Disconfirmation & Sentiment
Derived signals from the MCH market-data store (Alpha Vantage transcripts + news). Quantitative tone only — a disconfirmation flag, not a substitute for reading the call.
Management vs analyst tone (2026Q1): management +0.56 vs analyst floor +0.38 → delta +0.18 (n=25 mgmt / 13 Q&A; 11th pctile across the S&P book, z -1.3).
Flag: CANDID — management unusually candid/cautious vs peers (relatively low spin).
| Quarter | Mgmt | Analyst | Delta |
|---|---|---|---|
| 2026Q1 | +0.56 | +0.38 | +0.18 |
| 2025Q4 | +0.55 | +0.00 | +0.55 |
| 2025Q3 | +0.51 | +0.26 | +0.25 |
| 2025Q2 | +0.50 | +0.30 | +0.20 |
News (last 365d, 985 articles): avg ticker sentiment +0.21 (bullish 28% / bearish 2%)
Scenario Analysis
The tree runs from a structural 'Structural — Reimbursement / In-House Testing' downside ($90) to a 'Bull — Re-Rate' bull case ($361); the probability-weighted blend (PWEV $204) is -4% versus spot.
| Scenario | Probability | Target | Return |
|---|---|---|---|
| Structural — Reimbursement / In-House Testing | 20% | $90 | -58% |
| Volume Recession | 17% | $153 | -28% |
| Base — Volume + Acquisitions | 35% | $212 | +0% |
| Growth — Advanced-Diagnostics / M&A | 20% | $286 | +35% |
| Bull — Re-Rate | 8% | $361 | +71% |
| Probability-Weighted (PWEV) | — | $204 | -4% |
Scenario rationale — what each probability buys (the driver path behind every target):
- Structural — Reimbursement / In-House Testing (20%, $90). Structural impairment — reimbursement / in-house testing: earnings AND the multiple compress together. Target sits below the 52-week low by construction. Drivers — implied_target: 89.87; probability: 0.2.
- Volume Recession (17%, $153). Cyclical downturn — diagnostic test volumes + reimbursement rates + advanced-test mix + M&A weakens for 1–2 years before normalising. Drivers — implied_target: 152.62; probability: 0.17.
- Base — Volume + Acquisitions (35%, $212). Mid-cycle — normalised diagnostic test volumes + reimbursement rates + advanced-test mix + M&A; disciplined capital allocation; steady returns. Drivers — implied_target: 211.97; probability: 0.35.
- Growth — Advanced-Diagnostics / M&A (20%, $286). Upside — advanced diagnostics + M&A lifts earnings above mid-cycle; the multiple expands modestly. Drivers — implied_target: 286.15; probability: 0.2.
- Bull — Re-Rate (8%, $361). Upside tail — sustained tight conditions or a structural re-rate on advanced diagnostics + M&A. Drivers — implied_target: 361.4; probability: 0.08.
Valuation Triangulation
Five anchors — but read them with their basis in mind. The Monte Carlo, the DCF terminal, and the peer re-rate all key off a market multiple, so they are not fully independent; only the discounted cash flows themselves are genuinely multiple-free. The discipline is to read the spread and weight the cash-based view, not to treat five numbers as five independent votes.
| Method | Basis | Fair Value | vs Spot |
|---|---|---|---|
| Monte Carlo median (Student-t + regime) | multiple | $189 | -11% |
| Peer P/E re-rate | multiple | $155 | -27% |
| Peer EV/Revenue re-rate | multiple | $62 | -71% |
| Scenario PWEV | multiple | $204 | -4% |
| DCF (5-year + terminal) | cash flow + terminal × | $114 | -46% |
| Triangulated (weighted) | — | $159 | -25% |
Rating vs blend — the key debate. The rating tracks the multiple-discipline fair value (Monte Carlo $189 + scenario PWEV $204, ≈ spot); the weighted blend $159 (-25%) sits below it because the cash-flow DCF ($114) is materially more conservative than the market multiple. Whether the current multiple is justified is the central question for this name — and the principal downside risk to the rating.
Monte Carlo — the distribution, not a point
10,000 paths, Student-t shocks (fat tails) with a regime-switching overlay. The median lands at $189 and 41% of paths finish above spot. The variance decomposition shows the gross margin is the dominant swing factor (57% of variance). The fundamental driver, not the multiple, sets the spread — a cleaner setup.
DCF — the cash-flow anchor
Independent of the market multiple: a 5-year path, WACC 8.5%, 16x terminal FCF multiple → $114. This anchor is deliberately the heaviest (41%): it is the valuation least hostage to the current multiple regime.
Peer benchmarking — relative value
Against the peer cohort, re-rating to the peer-median forward multiple (P/E 14.455x) implies $155. A premium is only justified by superior growth/margins; otherwise it is multiple risk. Weighted just 12% so the market's mood does not drive the fair value.
Across all anchors the spread is wide (genuine disagreement — low valuation confidence).
Revenue-Segment Breakdown
The company-specific drivers behind the valuation — each segment carries its own growth, margin, multiple and capex intensity. (Tags: FACT reported · ESTIMATE from disclosures · INFERENCE judgment.)
| Segment | Revenue | Mix | Growth | Op margin | Multiple | Capex % | Tag |
|---|---|---|---|---|---|---|---|
| Diagnostics & Lab Services | $11.3B | 100% | 3% | 14% | 19x | 5% | ESTIMATE |
Named Exposures
Demand & pricing cycle (FACT/ESTIMATE)
| Dimension | Assessment |
|---|---|
| driver | diagnostic test volumes + reimbursement rates + advanced-test mix + M&A |
| net_debt_or_cash_b | -6.59 |
Capital intensity & shareholder returns (ESTIMATE)
| Dimension | Assessment |
|---|---|
| capex_pct_revenue | 0.05 |
| div_yield | 0.0161 |
Structural risk vs optionality (INFERENCE)
| Dimension | Assessment |
|---|---|
| downside | reimbursement / in-house testing |
| upside | advanced diagnostics + M&A |
Industry Context — Health Services
This name sits in the Health Services as a diagnostics. diagnostic test volumes + reimbursement rates + advanced-test mix + M&A Its scenarios are not guessed in isolation — they inherit a single, shared view of the cluster's driver cycle, so the names that depend on the same event are mutually consistent.
Value chain: MCK (distributors) · COR (distributors) · CAH (distributors) · DGX (diagnostics) · LH (diagnostics) · HSIC (distributors)
| Shared state | Capex path | House view | This name implies |
|---|---|---|---|
| Reimbursement / Disintermediation Pressure | 37% | 37% | |
| Mid-Cycle — Volume + Specialty Growth | 35% | 35% | |
| Upside — Specialty / M&A Re-Rate | 28% | 28% |
On the cluster's key downside — Reimbursement / Disintermediation Pressure () — this name implies 37% vs the cluster house view of 37% (in line with the house). The cluster's full cross-stock reconciliation governs that the names which ride the same capex cycle assign it comparable odds.
Structure: Shared State — The health_services cycle is the shared macro driver. Driver — drug/lab volumes + reimbursement + thin-margin distribution & specialty mix Dispersion — Members differ by cyclicality (quality compounders vs deep cyclicals).
Model Appendix
DCF — line items
| Year | Revenue | Op income | − Capex | + D&A | FCF | PV(FCF) |
|---|---|---|---|---|---|---|
| FY+1 | $12B | $2B | $1B | $1B | $1B | $1B |
| FY+2 | $12B | $2B | $1B | $1B | $1B | $1B |
| FY+3 | $12B | $2B | $1B | $1B | $1B | $1B |
| FY+4 | $13B | $2B | $1B | $1B | $1B | $1B |
| FY+5 | $13B | $2B | $1B | $1B | $1B | $1B |
| Terminal | — | — | — | — | $1B × 16x | $14B |
FCF is bridged: NOPAT + D&A − Capex − ΔNWC (capex intensity 5% of revenue, weighted from the segments) — not a single conversion fudge.
WACC 8.5% · Σ PV(FCF) $5B + PV(terminal) $14B = EV $19B; + net cash → equity $13B ÷ diluted shares 0.11B = $114/share (exit-multiple terminal).
- Gordon (perpetuity-growth) terminal at 2.5% → $123/share — a genuinely non-multiple, cash-based cross-check; the exit-multiple and Gordon values bracket the terminal-value risk.
- Incremental ROIC on the forecast capex ≈ 6% vs WACC 8% → below WACC — the incremental build is value-dilutive.
Peer set
| Peer | EV/Rev | Fwd P/E | Growth | Op margin |
|---|---|---|---|---|
| CVS | 0.49x | 14.2x | 8% | 4% |
| CI | 0.353x | 9.29x | 8% | 6% |
| LH | 1.98x | 14.79x | 3% | 11% |
| DVA | 1.897x | 14.71x | 4% | 14% |
| Median | 1.1935x | 14.455x | — | — |
Peer-median fwd P/E → $155; EV/Rev → $62.
Weighted fair-value math
| Anchor | Value | Weight | Contribution |
|---|---|---|---|
| DCF | $114 | 41% | $47 |
| Scenario PWEV | $204 | 29% | $60 |
| Monte Carlo median | $189 | 18% | $33 |
| Peer P/E | $155 | 12% | $18 |
| Triangulated | — | 100% | $159 |
Sensitivity
DCF/share — WACC × terminal multiple
| WACC ＼ Term× | 11.2x | 13.6x | 16.0x | 18.4x | 20.8x |
|---|---|---|---|---|---|
| 6% | $87 | $108 | $129 | $150 | $171 |
| 8% | $81 | $101 | $121 | $142 | $162 |
| 8% | $76 | $95 | $114 | $133 | $153 |
| 10% | $70 | $89 | $107 | $126 | $144 |
| 10% | $65 | $83 | $101 | $118 | $136 |
DCF/share — revenue CAGR Δ × op-margin Δ
| CAGRΔ ＼ MgnΔ | -3.0pp | -1.5pp | +0.0pp | +1.5pp | +3.0pp |
|---|---|---|---|---|---|
| -3.0pp | $64 | $80 | $97 | $114 | $130 |
| -1.5pp | $70 | $88 | $105 | $123 | $141 |
| +0.0pp | $76 | $95 | $114 | $133 | $152 |
| +1.5pp | $83 | $103 | $123 | $144 | $164 |
| +3.0pp | $90 | $111 | $133 | $155 | $176 |
Tornado — DCF/share swing by driver (widest first)
| Driver | Low | High | Swing |
|---|---|---|---|
| Op margin ±3pp | $76 | $152 | $76 |
| Terminal × ±15% | $95 | $133 | $39 |
| Revenue CAGR ±3pp | $97 | $133 | $36 |
| WACC ±1pp | $107 | $121 | $14 |
| FCF conversion ±10% | $114 | $114 | $0 |
Company lever — SoP/share vs Diagnostics & Lab Services multiple (AI re-rating) (base 19x)
| Multiple | 13.3x | 16.1x | 19.0x | 21.8x | 24.7x |
|---|---|---|---|---|---|
| SoP/share | $1,295 | $1,580 | $1,875 | $2,160 | $2,455 |
Load-Bearing Assumptions
DCF: WACC 8%, terminal multiple 16×, FY+5 revenue $13B. Triangulation leans 41% on DCF, 29% on PWEV.
Reasons the Thesis Could Fail (Falsifiable)
A miss on Gross Margin drops the case toward the structural target $90.
Fact / Inference / Speculation
- FACT: Spot $212; 52-week range $162–$213; engine rating HOLD; base-case target $204 (-4%).
- INFERENCE: Triangulated FV $159 (-25%). Gross Margin explains 57% of Monte Carlo outcome variance — the single variable that decides which side is right.
- SPECULATION: At current prices the embedded bet is that Gross Margin surprises to the upside — Gross Margin carries 57% of outcome variance.
Recommendation: HOLD
Balanced: triangulated fair value $159 (-25% vs spot); the outcome hinges on Gross Margin. The debate is Gross Margin (57% of variance) — a fundamental call. SBC runs —M TTM (disclosed in the appendix).